REPORT: Employees At Penguin Random House Cried Over The Decision To Publish Jordan Peterson’s Upcoming Book

News, market analysis, investment scam prevention tips and more ✔️ Your source for latest asset management news and information. This magazine is crafted specifically for those who are interested in diving into the global asset management world. Employees at Penguin Random House decried the publisher’s decision to move forward with Jordan Peterson’s latest book during a town hall, where they reportedly wept and expressed fear over the decision, according to Vice News.The workers at the publisher’s Canada location told Vice News that during the town hall to discuss Peterson’s upcoming book, “Beyond Order,” people described the author as an “icon of hate speech” who had radicalizing abilities. Source: Screenshot/Youtube/GWPF “He is an icon of hate speech and transphobia and the fact that he’s an icon of white supremacy, regardless of the content of his book, I’m not proud to work for a company that publishes him,” one employee who went to the town hall told Vice. Another employee found it hypocritical that the company was publishing Peterson while also implementing “anti-racist and allyship” trainings. “People were crying in the meeting about how Jordan Peterson has affected their lives,” an employee told Vice, adding that a colleague had brought up how Peterson had allegedly radicalized their father. Another employee said that the book would be harmful for their non-binary friend. Peterson has faced similar accusations in the past, prior to stepping back To keep reading about REPORT: Employees At Penguin Random House Cried Over The Decision To Publish Jordan Peterson’s Upcoming Book, Click on the link. Seoul, Korea
http://dlvr.it/RmPl0R

Comments

Popular posts from this blog

AstraZeneca Begins Phase I Trial Of AZD7442 Against COVID-19 – Quick Facts

Coronavirus Hasn't Diminished Tech Stocks' Allure

Henlius Plans to File the NDA of Novel anti-PD-1 mAb HLX10 for the Treatment of MSI-H Solid Tumours, the Phase 2 Clinical Trial has Met the Primary Endpoint